Sarepta Therapeutics to Submit New Drug Application to FDA for Eteplirsen by the end of 2014 - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "Sarepta Therapeutics announced yesterday their plans to submit a new drug application (NDA) for eteplirsen to the US Food and Drug Administration (FDA) by the end of this year. Eteplirsen is Sarepta's lead candidate to skip exon 51."
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment